Egyptian renal data system (ERDS) 2020: an annual report of end-stage kidney disease patients on regular hemodialysis

Hassaballa, May; El-Wakil, Hala S; ElSharkawy, Magdy; Khamis, Said Sayed Ahmed; Tantawy, Tarek El; Wahby, Wael; Salem, Karem Mohamed; Gawad, Mohammed Abdel

doi:10.4103/jesnt.jesnt_37_21

Cited by 11 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study shows male predominance (58.9%) among our surveyed HD patients. This is in agreement with the latest published statistics from the Egyptian Renal Data System (ERDS) which shows a 58.7% male predominance in the Egyptian HD population [ 29 ]. The majority of surveyed individuals in the present study were unemployed highlighting the problem of unemployment in the HD population.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Egyptian hemodialysis patients' willingness to receive the COVID-19 vaccine booster dose: a multicenter survey

Abdulaziz

Saleh

Elrggal³

et al. 2023

J Nephrol

View full text Add to dashboard Cite

Background Health authorities have struggled to increase vaccination uptake since the COVID-19 vaccines became available. However, there have been increasing concerns about declining immunity after the initial COVID-19 vaccination with the emergence of new variants. Booster doses were implemented as a complementary policy to increase protection against COVID-19. Egyptian hemodialysis (HD) patients have shown a high rate of hesitancy to COVID-19 primary vaccination, yet their willingness to receive booster doses is unknown. This study aimed to assess COVID-19 vaccine booster hesitancy and its associated factors in Egyptian HD patients. Methods A face-to-face interview was conducted with closed-ended questionnaires distributed to healthcare workers in seven Egyptian HD centers, mainly located in three Egyptian governorates, between the 7th of March and the 7th of April 2022. Results Among 691 chronic HD patients, 49.3% (n = 341) were willing to take the booster dose. The main reason for booster hesitancy was the opinion that a booster dose is unnecessary (n = 83, 44.9%). Booster vaccine hesitancy was associated with female gender, younger age, being single, Alexandria and urban residency, the use of a tunneled dialysis catheter, not being fully vaccinated against COVID-19. Odds of booster hesitancy were higher among participants who did not receive full COVID-19 vaccination and among those who were not planning to take the influenza vaccine (10.8 and 4.2, respectively). Conclusion COVID-19 booster-dose hesitancy among HD patients in Egypt represents a major concern, is associated with vaccine hesitancy with respect to other vaccines and emphasizes the need to develop effective strategies to increase vaccine uptake. Graphical abstract

show abstract

Section: Discussionsupporting

confidence: 92%

“…The majority of surveyed individuals in the present study were unemployed highlighting the problem of unemployment in the HD population. This is again in agreement with the ERDS which stated that around 81.11% of Egyptian HD patients are either unemployed, retired, housewives, or students [ 29 ].…”

Section: Discussionsupporting

confidence: 89%

Egyptian hemodialysis patients' willingness to receive the COVID-19 vaccine booster dose: a multicenter survey

Abdulaziz

Saleh

Elrggal³

et al. 2023

J Nephrol

View full text Add to dashboard Cite

show abstract

“…The online sample size calculator RaoSoft ® was used to determine the appropriate sample size. Based on an estimated prevalence of patients on dialysis (264 pmp [ 11 ]), the 50% predicted response, 5% margin of error and 95% confidence level, the minimum sample size was 397 participants.…”

Section: Methodsmentioning

confidence: 99%

COVID-19 Vaccination Trends and Side Effects among Egyptian Hemodialysis Patients: A Multicenter Survey Study

et al. 2022

View full text Add to dashboard Cite

(1) Background: Vaccination may be a key intervention to prevent infection in chronic hemodialysis (CHD) patients. This study aimed to determine the COVID-19 vaccination status in Egyptian CHD patients and to analyze the safety and detailed side effect profile of the COVID-19 vaccine among these patients. (2) Methods: This survey-based study was conducted on 670 end-stage renal disease (ESRD) patients on CHD from 3 December 2021 to 5 February 2022. Subjects were asked about sociodemographic characteristics, clinical and therapeutic data, in addition to their COVID-19 vaccination status. If the subject had been vaccinated, we inquired about the type of vaccine and the side effects that occurred within a few days after administration of the first and second dose of the COVID-19 vaccine. Additionally, subjects were asked about the onset of side effects (days from vaccination), timing of maximum symptoms, intensity of symptoms and their effect on activity and need for medical attention. (3) Results: The study included 670 CHD patients with a mean age of 50.79 years; 58.1% were females. The vast majority (614; 91.6%) of the studied patients received two doses of the vaccine. Side effects were more commonly reported after the first dose than the second dose. The main side effects reported were generalized weakness/fatigue (56%), headache (43.8%) and fever (40.4%), and sore arm/pain was also reported (29.3%). Adverse events mostly occurred within one day after vaccination and the maximum symptoms usually happened on the second day. The median duration of symptoms was 3 days with a maximum duration up to 5 days. The univariate logistic regression analysis showed that male gender (OR 1.848; (95% CI, 1.242–2.749), p = 0.002), age (OR 0.981; (95% CI, 0.969–0.993), p = 0.003), smoking (OR 6.067; (95% CI, 3.514–10.475), p < 0.001), duration since starting HD (OR 0.998; (95% CI, 0.998–0.999), p < 0.001), associated comorbidities (OR 2.202; (95% CI, 1.478–3.281), p < 0.001) and prior COVID-19 infection (OR 3.318; (95% CI, 1.952–5.642), p < 0.001) were the main determinants of adverse events related to COVID-19 vaccination. (4) Conclusions: our preliminary findings support the favorable short-term safety profile of the COVID-19 vaccine among CHD patients, and hence can reassure both clinicians and patients, as well as further promote COVID-19 vaccine administration among these patients.

show abstract

“…Hypertension is the most common case of ESKD at 41%, followed by diabetes at 14%, whereas glomerulonephritis is the primary diagnosis in 3% of patients undergoing dialysis. The prevalence of unknown causes of ESKD varies between 13% (11) and 22% (12). Several studies have identified a high prevalence of CKD of unknown origin, ranging between 13% and 27% (11, 13).…”

Section: Demographics and Medical Characteristics Of Patients Undergo...mentioning

confidence: 99%

Global Dialysis Perspective: Egypt

Farag

El-Sayed²

2022

Kidney360

View full text Add to dashboard Cite

show abstract

Egyptian renal data system (ERDS) 2020: an annual report of end-stage kidney disease patients on regular hemodialysis

Cited by 11 publications

References 5 publications

Egyptian hemodialysis patients' willingness to receive the COVID-19 vaccine booster dose: a multicenter survey

Egyptian hemodialysis patients' willingness to receive the COVID-19 vaccine booster dose: a multicenter survey

COVID-19 Vaccination Trends and Side Effects among Egyptian Hemodialysis Patients: A Multicenter Survey Study

Global Dialysis Perspective: Egypt

Contact Info

Product

Resources

About